Skip to main
ATYR

ATYR Stock Forecast & Price Target

ATYR Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 40%
Buy 20%
Hold 40%
Sell 0%
Strong Sell 0%

Bulls say

aTyr Pharma Inc. demonstrates a strong positive outlook due to the promising results from its Phase II clinical trial of efzofitimod, which showed clinically meaningful lung function improvements while sparing steroid use in patients with pulmonary sarcoidosis. Additionally, interim data indicates the potential for significant improvement in modified Rodnan skin score (mRSS) in diffuse systemic sclerosis (SSc) patients, suggesting the efficacy of efzofitimod in other fibrotic conditions. The company's focus on expanding its pipeline with the possibility of approval in multiple indications, combined with projected market adoption, positions aTyr Pharma for substantial upside potential.

Bears say

The analysis indicates that aTyr Pharma's revenue opportunity has been significantly diminished due to a clinical setback associated with efzofitimod, with projections now seeing a reduced revenue potential of less than $300 million. Furthermore, there are concerns regarding the drug's developmental progress, as unexpected safety signals, regulatory approval failures, and other setbacks could lead to substantial downward revisions to financial estimates, with a potential downside fair value noted at $0.50 per share. Additionally, the failure in one indication has raised further risks to the drug's viability across other indications, despite some suggested activity observed in earlier trial phases.

ATYR has been analyzed by 5 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 20% recommend Buy, 40% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of aTyr Pharma Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About aTyr Pharma Inc (ATYR) Forecast

Analysts have given ATYR a Buy based on their latest research and market trends.

According to 5 analysts, ATYR has a Buy consensus rating as of Dec 29, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

aTyr Pharma Inc (ATYR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.